You are here: Industry Insights > Merck

News List

AstraZeneca and Merck establish strategic oncology collaboration worldpharmanews
July 28, 2017
AstraZeneca and Merck & Co., Inc., today announced that they have entered a global strategic oncology collaboration to co-develop and co-commercialise AstraZeneca's Lynparzafor multiple cancer types.
Merck wins tentative U.S. FDA approval for Lusduna biospectrumasia
July 27, 2017
LUSDUNA Nexvue is subject to an automatic stay due to a lawsuit from Sanofi claiming patent infringement.
Merck & Co.'s Keytruda fails to improve overall survival in head and neck cancer study firstwordpharma
July 26, 2017
Merck & Co. announced that the Phase III KEYNOTE-040 study of Keytruda (pembrolizumab) in previously treated patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) failed to meet its pre-specified primary endpoint of overall s
Merck launches Remicade biosimilar for all eligible indications, in the US cphi-online
July 26, 2017
The biosimilar's list price will represent a 35% discount to the current list price of Remicade.
Merck Announces U.S. Launch of RENFLEXIS americanpharmaceuticalreview
July 25, 2017
Merck announced the U.S. launch of RENFLEXIS (infliximab-abda), a biosimilar of the originator biologic medicine Remicade (infliximab).
Merck, Pfizer’s avelumab clears first hurdle in early access scheme pharmatimes
July 25, 2017
Patients with Merkel Cell Carcinoma living in the UK are a step closer to getting early access to Merck and Pfizer’s avelumab after regulators assigned the drug Promising Innovative Medicines (PIM) status.
Merck and Pfizer collaborate with Corning to modernize pharmaceutical glass packaging cphi-online
July 25, 2017
Collaborations result in development of Corning Valor Glass.
Tentative US approval for Merck’s diabetes therapy pharmatimes
July 24, 2017
The US Food and Drug Administration has given a tentative green light to Merck & Co’s follow-on biologic basal insulin Lusduna Nexvue.
Despite scoring an FDA nod, Merck's biosim Lusduna must wait to challenge Lantus fiercepharma
July 21, 2017
Sanofi’s top-selling Lantus is already contending with one copycat rival, and Merck & Co. just won FDA approval for another. Luckily for the $5 billion basal insulin, Merck’s new Lusduna Nexvue has to sit on the sidelines for now—and maybe for more than a
Merck Biopharma Innovation Cup 2017 worldpharmanews
July 18, 2017
Merck, a leading science and technology company, announced the winners of its seventh Biopharma Innovation Cup. The winning team received €20,000 for its innovative idea around the role of Natural Killer (NK) cells in cancer immunology.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 51 52 Next page